• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    European Cardiology Review

    European Cardiology Review

    JournalISSN 1758-3756eISSN 1758-3756中科院 医学 3区

    年发文量

    研究主题

    论文(1008)

    排序
    1Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence
    Shun Wen Chew, Jasmine Cheong Zhen Yi, Samuel Lim Jian Rong, Nicholas Yip Zhe Wei,Mohd Shawal Faizal Mohamad,Chim C Lang,Anna-Maria Choy

    Background: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy, microvascular dysfunction and chronic energetic inefficiency. Current therapies relieve symptoms or left ventricular outflow tract obstruction but do not directly target these metabolic abnormalities. Methods: We systematically searched PubMed, Embase, Google Scholar and ClinicalTrials.gov from 1 January 2000 to 31 May 2025 for randomised trials, observational cohorts, registries and case series (≥3 patients) evaluating fatty acid oxidation inhibitors (perhexiline, trimetazidine), late sodium current inhibition (ranolazine) or sodium–glucose cotransporter 2 inhibitors (SGLT2I) in adults with HCM. Outcomes included exercise capacity, diastolic indices, symptoms, arrhythmia burden and safety. Results: Seven HCM-specific studies met inclusion criteria: trimetazidine (one randomised controlled trial [RCT]), perhexiline (one RCT), ranolazine (one RCT, one real-world cohort and one case series) and SGLT2I (one prospective controlled cohort, one nationwide registry). Most enrolled predominantly non-obstructive or mixed HCM. Trimetazidine had neutral effects on peak VO₂, diastolic function and biomarkers. Perhexiline improved phosphocreatine-to-adenosine triphosphate ratios, diastolic indices, peak VO₂ and New York Heart Association class. Ranolazine consistently reduced angina and ventricular ectopy but did not increase peak VO₂. In the included HCM studies, empagliflozin/dapagliflozin exposure in a small prospective cohort was associated with improved E/e′ and New York Heart Association class, while broader SGLT2I use in a diabetic HCM registry was associated with lower mortality and hospitalisation for heart failure. Conclusion: Metabolic modulators and SGLT2I could improve diastolic parameters, symptoms and arrhythmia burden in selected, mainly non-obstructive HCM populations but have not demonstrated consistent gains in exercise capacity. Larger, phenotype-stratified randomised trials are needed to define their role alongside contemporary HCM therapies.

    2026
    引用
    AI阅读
    加入学术空间
    2Post-COVID Cardiac Symptoms in the Absence of Epicardial Stenoses: Potential Association with Persistent Coronary Microvascular Dysfunction
    Peter Ong,Basmah Safdar, Gerd Heusch
    2026
    引用
    AI阅读
    加入学术空间
    3Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management
    María Teresa Basurte-Elorz, Gemma Lacuey-Lecumberri,Nerea Mora-Ayestarán

    Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy increasingly recognised as a cause of heart failure. Advances in the understanding of its pathophysiology have enabled the development of targeted therapies, making ATTR-CM a paradigm of precision medicine in cardiology. Currently approved disease-modifying therapies, including two stabilisers (tafamidis and acoramidis) and one gene-silencing agent (vutrisiran), slow disease progression and reduce hospitalisations and mortality, particularly when initiated early. Because these therapies do not reverse established amyloid deposition, supportive management remains a critical component of care and presents distinct challenges. These include universal anticoagulation in AF, careful diuretic management, the benefits of sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists, and limited tolerance to other foundational heart failure therapies. On-going intensive research is expanding the therapeutic landscape, with several Phase III trials evaluating next-generation silencers, gene-editing strategies and amyloid-removal therapies. While these advances hold promise for disease reversal and prevention, important unresolved issues arise, including optimal treatment selection, monitoring strategies and economic sustainability.

    2026
    引用
    AI阅读
    加入学术空间
    4Letter to the Editor Regarding “lifetime Management in Transcatheter Aortic Valve Implantation”
    Aysha Hashmi
    2026
    引用
    AI阅读
    加入学术空间
    5Risk–Benefit Profile of Oral Antiplatelet Strategies after Percutaneous Coronary Intervention with a Drug-eluting Stent: A Contemporary Network Meta-analysis of Major Bleeding and Stent Thrombosis Outcomes
    Suryono,Muhammad Farhan Hibatulloh,Alfiyah Ramadhani, Candra Agung Wibisana,Muhammad Naufal Hibatullah,Achmad Ilham Tohari,Muhammad Rijal Fahrudin Hidayat, Muhammad Irsyad Amien, Hazbina Fauqi Ramadhan

    Background: Optimal antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) requires balancing thrombotic protection and bleeding risk, but the comparative effectiveness of current strategies remains uncertain. Aims: To evaluate the risk–benefit profile of oral antiplatelet strategies after PCI with DES, focusing on major bleeding and stent thrombosis. Methods: A network meta-analysis of randomised and observational studies was conducted. Strategies included standard or extended dual antiplatelet therapy (DAPT), shortened DAPT followed by monotherapy and P2Y12 inhibitor-based monotherapy. Outcomes were analysed using a random-effects model and ranked with p-scores. Evidence certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: Thirty studies involving 110,035 patients were included. Ticagrelor monotherapy ranked highest for reducing major bleeding, whereas extended DAPT provided the greatest protection against stent thrombosis, with clopidogrel-based therapy beyond 12 months ranking highest (RR 0.08; 95% CI [0.01–0.52]; p-score=0.94). Notably, clopidogrel monotherapy after prolonged DAPT demonstrated a relatively balanced profile across both outcomes. However, no strategy was consistently optimal and most estimates showed wide CIs. Conclusion: Antiplatelet strategies after PCI with DES involve a clear trade-off between bleeding and thrombotic risk. Clopidogrel monotherapy after prolonged DAPT may offer a balanced approach, although findings should be interpreted cautiously due to limited precision and consistency.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1008 篇论文

    高被引作者

    作者引用发文
    Dimitris Tousoulis19376
    Georgia Vogiatzi18191
    Alexios S. Antonopoulos18191
    Sotirios Tsalamandris18191
    George Aggelos Papamikroulis18191
    Papaioannou Spyridon18191
    Jason Andrade7753
    Marc Deyell7652
    Laurent Macle7652
    Allan C. Skanes6741

    高产作者

    作者引用发文
    Koji Hasegawa24740
    Yoichi Sunagawa11419
    Tatsuya Morimoto11418
    Hiromichi Wada10218
    Antoni Martinez-Rubio2317
    Maki Komiyama11715
    Miyazaki Yusuke11215
    Yasufumi Katanasaka11215
    Masafumi Funamoto11415
    Kana Shimizu11314

    相关期刊

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
    IAPAC monthly
    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
    Archives of Cardiovascular Diseases
    Therapeutic advances in cardiovascular disease
    Acta Cardiologica Sinica
    Cardiology in Review
    Archivos de Cardiologia de Mexico
    World Journal of Cardiology
    MINERVA CARDIOLOGY and ANGIOLOGY